MFDS Approves Qinlock, an Orphan Drug for Gastrointestinal Stromal Tumors
The Ministry of Food and Drug Safety said it approved Qinlock 50 mg tablets (ripretinib) on October 16 for the treatment of gastrointestinal stromal tumors.
Gastrointestinal stromal tumors are tumors that develop in the tissues forming the walls of the stomach or intestines.
Qinlock is used to treat adults with advanced gastrointestinal stromal tumors who have previously been treated with three or more kinase inhibitors, including imatinib. It is classified as an imported orphan drug.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The Ministry of Food and Drug Safety said, "This medicine may offer a new treatment option by inhibiting tyrosine kinases involved in the growth of cancer cells."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.